Ozempic / Wegovy (Semaglutide): An honest audit
Weekly GLP-1 receptor agonist injection for weight loss and T2D
6/10
Sustainability
9/10
Short term
7/10
Long term
Three numbers, one rubric
Category
Pharma
Typical cost
~$1100/mo
First visible change
~28 days
Evidence rating
Strong evidence
Studies cited
8
How to read these scores
Sustainability
Weighted heaviest. Adherence predicts outcome more reliably than macro split, so an approach nobody can keep scores low here even when the trial data looks good.
Short-term effect
A high number here alone means very little. Water and glycogen move fast, and almost every restrictive protocol looks impressive at week four.
Long-term effect
Where short-term and long-term diverge sharply, you are usually looking at a regain mechanism built into the design — not a willpower failure.
What it promises — and how it says it works
The claim
What it claims
Semaglutide (Ozempic for type-2 diabetes, Wegovy for weight management) is a once-weekly injectable GLP-1 receptor agonist that promises substantial weight loss (14-15% mean reduction at 68 weeks per the STEP 1 trial), improved glycemic control, and reduced cardiovascular events. The drug mimics a naturally occurring incretin hormone, slowing gastric emptying, suppressing glucagon, and acting centrally on appetite-regulating circuits in the hypothalamus and brainstem. Marketing claims and clinician messaging emphasise that semaglutide is a treatment for the disease of obesity, not a cosmetic shortcut, and that the weight loss is durable so long as treatment continues. The strongest claim is that semaglutide is now the most effective non-surgical weight-loss intervention in trial history, with cardiovascular benefit (SELECT) extending the use case to obesity without diabetes.
The mechanism
How it is supposed to work
Semaglutide is a GLP-1 analogue with a 7-day half-life enabled by albumin binding. GLP-1 receptors are expressed centrally (hypothalamus, brainstem area postrema, vagal afferents) and peripherally (pancreatic beta cells, gastric smooth muscle). The drug reduces appetite via central pathways, slows gastric emptying (producing earlier satiety and prolonged fullness), suppresses postprandial glucagon, and stimulates glucose-dependent insulin secretion. Weight loss is primarily driven by reduced caloric intake — STEP trial participants spontaneously consumed several hundred fewer calories per day. This is a calorie-deficit mechanism mediated pharmacologically, not a unique metabolic effect. The drug does not increase energy expenditure meaningfully. Loss of muscle and bone mass during weight loss is therefore the same problem as with any rapid weight-loss intervention — and is documented in trial substudies.
What the research actually shows
The STEP 1 trial¹ (Wilding 2021, NEJM) produced 14.9% mean body-weight reduction at 68 weeks vs 2.4% with placebo. STEP 5² extended this to 15.2% at 104 weeks. STEP 2³ in T2D produced 9.6% loss. SURMOUNT-1 (tirzepatide, the dual GLP-1/GIP) topped this at 20.9%. The SELECT trial⁴ (Lincoff 2023) showed a 20% reduction in major adverse cardiovascular events in obese non-diabetic adults — extending the indication. But the STEP 1 extension⁵ documented the discontinuation problem: at one year off the drug, two-thirds of weight was regained and most cardiometabolic improvements reversed. Body-composition substudies⁶ show ~25-40% of total weight lost is lean mass — a sarcopenia risk especially relevant for older adults and women. Jensen 2024⁷ showed bone-mineral-density loss at hip and spine on GLP-1 monotherapy that was prevented by concurrent exercise. Side effects (gastroparesis, gallstones, possible pancreatitis, nausea) are real but typically manageable; long-term effects are still emerging.¹²³⁴⁵⁶⁷⁸
Footnote numbers link to the full reference list at the foot of this page.
Evidence rating
Strong evidence
Describes the quality and quantity of the peer-reviewed literature — trial count, duration, sample size and replication — not our opinion of the approach.
Early loss is not evidence. Glycogen carries roughly three grams of water per gram, so the first pounds on almost any restrictive protocol are largely water. What matters is what is still there at twelve and twenty-four months.
Right person, wrong person
Almost nothing on this site is universally good or universally useless. The useful question is which body, kitchen and calendar an approach was built for.
Worth a trial
Who it works for
Semaglutide is genuinely indicated for adults with BMI ≥30 (or ≥27 with comorbidities), particularly those with type-2 diabetes, established cardiovascular disease, prediabetes, or significant obesity-related comorbidity. It works for adults who have made multiple serious lifestyle attempts and not achieved meaningful weight loss. It works for adults willing to commit to indefinite treatment plus a serious lifestyle protocol — not as a 12-week course followed by a return to prior eating. It is increasingly recommended for older adults whose obesity is driving frailty and metabolic disease, provided active countermeasures (resistance training, 1.6-2.0 g/kg protein, calcium/vitamin D adequacy) prevent muscle and bone loss.
Look elsewhere
Who it fails
Semaglutide is poor fit for adults with 15-25 lbs to lose who are otherwise healthy — the cost (~$1000-1500/mo without insurance), side-effect profile, lean-mass-loss risk, and rebound dynamics don't justify the use. It fails for adults who cannot or will not pair the drug with strength training and adequate protein, accelerating sarcopenia. It fails for adults who view it as a temporary intervention rather than a long-term commitment — the regain on discontinuation is the rule, not the exception. It can fail for adults with eating-disorder history (the appetite suppression can interact poorly with restrictive patterns). The shortage / supply-chain volatility means access is inconsistent for many.
GLP-1 drugs are the most effective non-surgical weight-loss intervention in trial history, and SELECT extends their value to cardiovascular protection. The honest position is neither anti-pharma nor pro-pharma: these drugs work, work better with serious lifestyle scaffolding, probably need to be lifelong for many users, and require active countermeasures against muscle and bone loss. The cultural framing as a cosmetic shortcut for vanity weight loss in healthy adults is genuinely problematic — those are not the patients in the pivotal trials. For the right patient (obesity with comorbidity, BMI ≥30, willing to commit to long-term treatment + lifestyle), the evidence supports use. For everyone else, the calculus is much less favourable.
Written against the rubric, not against a sponsor. Individual response varies and no outcome is guaranteed.
What to do instead
If your BMI is under 30 and you don't have diabetes or established CV disease: try a serious 12-month lifestyle protocol first (UPF reduction, 1.6 g/kg protein, resistance training 3x/week, sleep optimisation). If you're on GLP-1 already and want off: see /glp1/transitioning-off-ozempic — the post-discontinuation protocol is non-trivial.
Not sure which fits
Get a read on your profile
Fifteen questions, roughly two minutes, no email wall on the result. Returns a starter protocol matched to your metabolic situation.
Take the assessmentStraight answers
Ozempic / Wegovy (Semaglutide), without the spin
We score Ozempic / Wegovy (Semaglutide) 6/10 for sustainability, 9/10 for short-term effect and 7/10 for long-term effect. A gap between the short-term and long-term numbers is the single most common pattern in this index — an approach can move the scale quickly and still leave almost nothing behind eighteen months later.
Sustainability is weighted heaviest for a reason: across head-to-head trials, adherence predicts outcome more reliably than which named diet you picked. A protocol you abandon in week six did nothing at all.
Can you still be doing this in month twelve?
First 12 weeks in controlled trials
What survives at 12–24 months
Educational summaries of published research. Individual response varies and no outcome is guaranteed.
References
- 01Wilding JPH et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. PubMed 33567185
- 02Wilding JPH et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism. PubMed 35441470
- 03Jastreboff AM et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. PubMed 35658024
- 04Davies M et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). The Lancet. PubMed 33667417
- 05Garvey WT et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nature Medicine. PubMed 36280412
- 06Lincoff AM et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. PubMed 37952131
- 07Linge J et al. (2024). Body composition and cardiometabolic effects of GLP-1 receptor agonists: changes in lean mass. Obesity Reviews. PubMed 38605467
- 08Jensen SBK et al. (2024). Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment. JAMA Network Open. PubMed 38904957
Did Ozempic / Wegovy (Semaglutide) not work for you?
That is the rule rather than the exception, and it is usually a design problem in the protocol rather than a character problem in you. The assessment reads your situation and points you at the approach the research supports for that profile.
- Free, with no email wall on the result
- Fifteen questions, roughly two minutes
- Returns a starter protocol matched to your profile
- Every recommendation links back to its research
Educational only, not medical advice. This audit summarises published research and is not a diagnosis, a prescription, or a treatment plan. Consult your physician before major dietary changes or altering prescribed medication. These statements have not been evaluated by the Food and Drug Administration. Individual results vary; no outcome is guaranteed.